Repros Therapeutics Inc.(R) Announces Pricing of Public Offering of Common Stock

Repros Therapeutics Inc.(R) Announces Pricing of Public Offering of Common
Stock

THE WOODLANDS, Texas, June 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc. (Nasdaq:RPRX) today announced the pricing of an underwritten public
offering of 3,750,000 shares of its common stock at a public offering price of
$19.00 per share, before underwriting discounts and other offering expenses.
The gross proceeds from the sale of the shares, before underwriting discounts
and other offering expenses, are expected to be $71.25 million. The offering
is expected to close on June 25, 2013, subject to customary closing
conditions. Repros Therapeutics has also granted the underwriters a 30-day
option to purchase up to 562,500 additional shares of common stock. All of the
shares in the offering are to be sold by Repros Therapeutics Inc.

In connection with this offering, BofA Merrill Lynch is acting as the sole
book-running manager and Lazard Capital Markets LLC, Ladenburg Thalmann & Co.
Inc. and Ascendiant Capital Markets, LLC are acting as co-managers.

The securities described above are being offered by Repros Therapeutics
pursuant to a shelf registration statement filed by Repros Therapeutics with
the Securities and Exchange Commission (SEC) and declared effective.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such state or other jurisdiction.

The offering may be made only by means of a prospectus supplement and
accompanying base prospectus meeting the requirements of Section 10 of the
Securities Act of 1933, as amended. A preliminary prospectus supplement
related to the offering was filed with the SEC on June 17, 2013 and a final
prospectus supplement relating to the offering will be filed with the SEC and
will be available, free of charge, on the SEC's website located at
www.sec.gov. Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering, when available, may be obtained from the
offices of: BofA Merrill Lynch, 222 Broadway, New York, New York 10038,
Attention: Prospectus Department or by emailing
dg.prospectus_requests@baml.com.

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Forward-Looking Statements

Statements contained in this press release about Repros Therapeutics that are
not purely historical, and all other statements that are not purely
historical, may be deemed to be forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of
1995. The words "anticipates," "believes," "estimates," "expects," "intends,"
"may," "plans," "projects," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Forward-looking
statements in this press release involve known and unknown risks and
uncertainties that may cause Repros Therapeutics' actual results, levels of
activity, performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Important factors that
may cause or contribute to such differences include whether or not Repros
Therapeutics will consummate the offering at all or on the anticipated terms
of the offering, fluctuations in Repros Therapeutics' stock price, the
anticipated use of the proceeds of the offering, Repros Therapeutics' ability
to satisfy customary closing conditions related to the proposed offering, and
such other factors as are set forth in the risk factors detailed from time to
time in the Repros Therapeutics' periodic reports and registration statements
filed with the SEC including, without limitation, the risk factors detailed in
the Repros Therapeutics' Annual Report on Form 10-K for the year ended
December 31, 2013 and the preliminary prospectus supplement Repros
Therapeutics has filed with the SEC under the heading "Risk Factors." You
should not place undue reliance on these forward-looking statements. In
addition, any forward-looking statements represent Repros Therapeutics' views
only as of today and should not be relied upon as representing Repros
Therapeutics' views as of any subsequent date. Repros Therapeutics disclaims
any obligation to update any forward-looking statements.

CONTACT: Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931
         thoffmann@troutgroup.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.